Clinical trials are an important step in discovering new treatments as well as new ways to detect, diagnose, and reduce the risk of disease. Clinical trials show what does and doesn’t work in people, and also helps the medical teams decide if the side effects of a new treatment are acceptable when weighed against the benefits offered by the new treatment.

The following organizations conduct clinical trials. Please visit these websites directly to learn what trials are in progress.

Industry News Articles & Updates

Drug Duo Granted Breakthrough Status to Treat Endometrial Cancer

August 2, 2018: Cure – The FDA has granted a breakthrough therapy designation to the combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair endometrial carcinoma who have progressed after at least one prior systemic therapy. Read more.


Apatinib–etoposide shows promise in platinum-resistant ovarian cancer

Apatinib–etoposide shows promise in platinum-resistant ovarian cancer August 15, 2018: Medwire News – Oral etoposide plus apatinib is associated with a good objective response rate and manageable toxicity in heavily pretreated Chinese women with platinum-resistant or refractory ovarian cancer, according to results of the phase II AEROC study. Read more.


FDA Approves Maintenance Rucaparib for Ovarian Cancer

The FDA has approved rucaparib (Rubraca) tablets for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the manufacturer of the PARP inhibitor. Read more on this story from: OncLive  Medscape  Clinical Oncology News